Tumor progression and metastasis are in part driven by proliferating microvessels that provide oxygen and nutrients to the growing cancer cells. Angiogenic vessels exert an instructive role as a vascular niche by providing paracrine and angiocrine modes of regulation which include secretion and processing of various growth factors and extracellular matrix constituents that in turn influence tumor and endothelial cells in a bidirectional way. Perlecan, a major heparan sulfate proteoglycan secreted by endothelial cells, is a complex regulator of vascular biology and tumor angiogenesis. Perlecan shows a clear functional dichotomy. The parent proteoglycan is pro-angiogenic by acting as a co-receptor for FGF2 and VEGFA via the N-terminal heparin sulfate chains. In contrast, the C-terminal portion of perlecan, named endorepellin, is anti-angiogenic. We have recently discovered that endorepellin binds with high affinity to both ?2?1 integrin and VEGFR2. This dual receptor binding induces co-internalization and physical downregulation of both receptors, activation of SHP-1 and attenuation of VEGFA transcription. These findings provide a new paradigm for the activity of an anti-angiogenic protein and mechanistically explain the specificity of endorepellin for endothelial cells, the only cells that simultaneously express both ?2?1 integrin and VEGFR2. Our long-term objectives are to expand these observations by investigating the binding mode of endorepellin and its various LG modules to the ectodomain of VEGFR2, and decipher the downstream signaling pathway evoked by this natural antagonist of two major angiogenic receptors. Specifically we plan to: [1] Investigate the precise mode through which endorepellin and its LG modules bind to the ectodomain of VEGFR2. [2] Decipher the downstream signaling pathways evoked by endorepellin on vascular endothelial cells, and [3] Generate novel mouse models of tumorigenesis where endorepellin and perlecan are conditionally overexpressed or ablated, respectively, in the endothelia of growing tumors. The expected results should generate a coherent and unified mode of action for endorepellin, identify new target proteins involved in its signaling pathway which could be potential novel targets for anti-angiogenesis therapy, and establish its in vivo role as an anti-angiogenic factor using unambiguous gain- and loss-of-function experiments through endothelial cell-specific gene targeting.

Public Health Relevance

This proposal is based on the discovery that endorepellin, a fragment of perlecan, exhibits potent angiostatic activity via a dual receptor antagonism to regulate angiogenesis. Deciphering the precise mode of action for endorepellin and being able to directly target established tumor vasculature would be of substantial benefit to future anti-angiogenic therapies, not only for cancer but also for other pathologies where angiogenesis plays a pivotal role.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
2R01CA047282-21A1
Application #
8503101
Study Section
Intercellular Interactions (ICI)
Program Officer
Woodhouse, Elizabeth
Project Start
1990-08-06
Project End
2018-04-30
Budget Start
2013-07-01
Budget End
2014-04-30
Support Year
21
Fiscal Year
2013
Total Cost
$356,235
Indirect Cost
$126,406
Name
Thomas Jefferson University
Department
Pathology
Type
Schools of Medicine
DUNS #
053284659
City
Philadelphia
State
PA
Country
United States
Zip Code
19107
Neill, Thomas; Buraschi, Simone; Goyal, Atul et al. (2016) EphA2 is a functional receptor for the growth factor progranulin. J Cell Biol 215:687-703
Poluzzi, Chiara; Iozzo, Renato V; Schaefer, Liliana (2016) Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengers. Adv Drug Deliv Rev 97:156-73
Gubbiotti, Maria A; Neill, Thomas; Iozzo, Renato V (2016) A current view of perlecan in physiology and pathology: A mosaic of functions. Matrix Biol :
Neill, Thomas; Schaefer, Liliana; Iozzo, Renato V (2016) Decorin as a multivalent therapeutic agent against cancer. Adv Drug Deliv Rev 97:174-85
Hsieh, Louise Tzung-Harn; Frey, Helena; Nastase, Madalina-Viviana et al. (2016) Bimodal role of NADPH oxidases in the regulation of biglycan-triggered IL-1β synthesis. Matrix Biol 49:61-81
Schaefer, Liliana; Tredup, Claudia; Gubbiotti, Maria A et al. (2016) Proteoglycan neofunctions: regulation of inflammation and autophagy in cancer biology. FEBS J :
Buraschi, Simone; Xu, Shi-Qiong; Stefanello, Manuela et al. (2016) Suppression of progranulin expression inhibits bladder cancer growth and sensitizes cancer cells to cisplatin. Oncotarget 7:39980-39995
Goyal, Atul; Gubbiotti, Maria A; Chery, Daphney R et al. (2016) Endorepellin-evoked Autophagy Contributes to Angiostasis. J Biol Chem 291:19245-56
Iozzo, Renato V; Schaefer, Liliana (2015) Proteoglycan form and function: A comprehensive nomenclature of proteoglycans. Matrix Biol 42:11-55
Neill, Thomas; Schaefer, Liliana; Iozzo, Renato V (2015) Decoding the Matrix: Instructive Roles of Proteoglycan Receptors. Biochemistry 54:4583-98

Showing the most recent 10 out of 158 publications